Revance Therapeutics (RVNC) Misses Q1 EPS by 26c
Tweet
Share
E-mailGet Alerts RVNC Hot Sheet
Join SI Premium – FREE
Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.97), $0.26 worse than the analyst estimate of ($0.71).
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
- Kustom Entertainment agrees to buy Tickets For Less operator TFL
- Ferrari completes €250M buyback tranche, launches third
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
